Mepolizumab reduces exacerbations in COPD with type 2 …
WEB4 days ago · That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK in a company press release. The study tested mepolizumab against a placebo in adults with COPD and type 2 inflammation, which is marked by high blood counts of eosinophils, a type of immune cell. Mepolizumab is approved as Nucala for ...
GSK announces positive results from phase III trial of Nucala ...
WEBSep 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).
Mepolizumab Significantly Reduces COPD Exacerbations
WEBSep 12, 2024 · Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab compared with placebo among patients treated for up to 104 weeks.
GSK announces FDA approval for Nucala (mepolizumab) for …
WEBJul 29, 2021 · GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
FDA Approves First Drug to Treat Group of Rare Blood Disorders in ...
WEBSep 25, 2020 · Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without...
GSK announces phase III results published in NEJM of mepolizumab …
WEBSep 12, 2017 · Mepolizumab has been submitted for regulatory review for eosinophilic granulomatosis with polyangiitis (EPGA, also referred to as Churg-Strauss syndrome) and is being investigated for severe hypereosinophilic syndrome, …
Benralizumab versus Mepolizumab for Eosinophilic …
WEBFeb 23, 2024 · We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab.
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary …
WEBOct 26, 2017 · Mepolizumab, a humanized monoclonal antibody, reduces eosinophil counts in blood and tissues by blocking interleukin-5, a key eosinophil cytokine, through binding to eosinophil surface...
Mepolizumab Lessens Exacerbations, Improves Quality of Life
WEBAug 9, 2021 · Treatment with mepolizumab, an antibody designed to lower the levels of eosinophils — immune cells linked with worse chronic obstructive pulmonary disease (COPD) — was found to reduce the annual rate of exacerbations and improve health-related quality of life in people with eosinophil-associated COPD. The findings, from a …
Oral Glucocorticoid-Sparing Effect of Mepolizumab in …
WEBSep 25, 2014 · Mepolizumab, a humanized monoclonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma.